You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Acetylcholinesterase inhibitors partially generalize to nicotine discriminative stimulus effect in rats

Giarola, Alessandraa; Auber, Alessiab; Chiamulera, Cristianob

Behavioural Pharmacology:
doi: 10.1097/FBP.0b013e328341e9dd
Original Articles
Abstract

Acetylcholinesterase inhibitors (AChE-Is), galantamine, physostigmine and tacrine, enhance central levels of synaptic acetylcholine. Galantamine and physostigmine, but not tacrine, exhibit allosteric potentiation ligand (APL) properties on nicotinic acetylcholine receptors. The purpose of this study was to investigate whether AChE-Is with nicotinic acetylcholine receptor-positive allosteric modulator properties generalize to the discriminative stimulus effect of nicotine in rats. A two-lever operant conditioning paradigm was used in which rats were trained to discriminate nicotine (0.2 mg/kg/ml intraperitoneally) from saline. After training, generalization tests were carried out with galantamine (1, 3 or 5 mg/kg intraperitoneally), physostigmine (0.05, 0.1 or 0.2 mg/kg subcutaneously) or tacrine (0.625, 1.25 or 2.5 mg/kg subcutaneously) given as a single presession administration. Galantamine, physostigmine or tacrine produced a partial generalization of 62.2%, 55.1% or 43.6% , respectively, on the nicotine-appropriate lever compared with 100% partial generalization induced by the nicotine-training dose. High doses of galantamine, physostigmine or tacrine produced small but significant decreases in operant response rate, suggesting a possible underestimation of the degree of generalization. Our study showed that these three AChE-Is partially generalized to the nicotine stimulus without a significant distinction between AChE-Is with or without APL properties. These findings suggest that the APL property is not necessary for inducing nicotine-like effects in vivo in this behavioural paradigm.

Author Information

aSafety Pharmacology, Safety Assessment Department, GlaxoSmithKline R&D Centre

bDepartment of Public Health and Community Medicine, Section of Pharmacology, University of Verona, Verona, Italy

Correspondence to Dr Alessandra Giarola, Safety Pharmacology, Safety Assessment Department, GlaxoSmithKline R&D Centre, Via Fleming 2, 37135 Verona, Italy e-mail: alessandra.s.giarola@gsk.com

Received April 14, 2010

Accepted September 16, 2010

© 2011 Lippincott Williams & Wilkins, Inc.